Depemokimab is a medicine for severe asthma that is driven by a type of white blood cell called eosinophils. It is given as a shot under the skin and is added to a person's usual asthma medicines. It works by blocking a signal that tells the body to make these cells, which helps calm swelling in the airways.
Every report comes from a Lived member, sent anonymously.
Have you tried Exdensur (Depemokimab) for Asthma?
Depemokimab, sold as Exdensur, is a biologic injection for severe asthma driven by eosinophils, a type of white blood cell that can build up in the airways and fuel inflammation. In the US it is approved as an add-on maintenance treatment for people aged 12 and older. It is added to existing asthma medicines, such as an inhaled steroid and a long-acting controller, rather than replacing them. It is meant for people whose asthma still flares despite strong inhaled treatment. In the studies that led to its approval, participants had needed steroid pills or shots for at least two flare-ups in the previous year and had raised eosinophil counts on a blood test. Doctors call this pattern eosinophilic asthma, and checking the blood eosinophil count is part of deciding whether a medicine like this is likely to help.
Depemokimab is a monoclonal antibody, a lab-made protein designed to attach to one specific target. Its target is interleukin-5 (IL-5), a chemical signal the body uses to produce eosinophils, call them into tissues and keep them alive. By blocking IL-5, depemokimab lowers the number of eosinophils, which in eosinophilic asthma is linked to fewer serious flare-ups. Asthma inflammation involves many cell types, though, and exactly how this translates into benefit is not fully understood. What sets depemokimab apart from similar medicines is how long it lasts. It carries a small engineered change that lets the body recycle the antibody instead of breaking it down, so it stays active for months. That is why it is given twice a year, while mepolizumab (Nucala), an older IL-5 blocker, is injected every four weeks.
Exdensur is a 100 mg injection under the skin of the upper arm, thigh or abdomen, given once every six months. A healthcare provider gives the injection, usually at a clinic visit, so it is not something people take home and inject themselves. If a scheduled dose is missed, it should be given as soon as possible, and the six-month schedule then restarts from that new date. Everyday asthma medicines, including the inhaled steroid and the rescue inhaler, continue as prescribed alongside it.
In clinical trials, the side effects reported more often than with placebo were colds and other upper respiratory infections, allergy-type nasal symptoms, flu, joint pain and sore throat. Each affected fewer than one in ten people taking it. About 1 in 100 people had redness, swelling or itching where the injection was given. Allergic reactions, including anaphylaxis, can occur after an injection. Hives, a rash or swelling of the face or lips after a dose should be reported to the care team right away. Trouble breathing, throat tightness, or feeling faint after an injection is an emergency: call 911.
Depemokimab does not stop an asthma attack in progress or relieve sudden symptoms. A rescue inhaler is still needed for that, and an asthma action plan stays in place. Do not stop or cut back inhaled or oral steroids on your own after starting depemokimab. Some people are eventually able to lower their steroid dose, but stopping abruptly can cause withdrawal symptoms or bring back conditions the steroids were keeping in check, so any reduction should be gradual and supervised. Eosinophils help the body fight parasitic worm infections. An existing worm infection should be treated before starting, and a new one that does not clear with treatment may mean pausing depemokimab. No formal drug interaction studies have been done. Because the antibody lasts so long, a baby exposed during pregnancy may end up with higher and longer-lasting levels of the medicine, and what that means for the baby is not yet known. Poorly controlled asthma also carries real risks in pregnancy, so anyone pregnant or planning a pregnancy should weigh this with their doctor rather than stopping treatment alone.
The main goal of depemokimab is fewer serious asthma flare-ups. In two year-long trials, people taking it had about half as many flare-ups needing steroid pills, an emergency visit or a hospital stay as people taking a placebo, and fewer of them had any flare-up at all (about a third, compared with about half). In those same trials, though, it did not improve breathing tests or day-to-day symptom scores more than placebo. Someone starting it should expect a change mainly in how often bad attacks happen, not necessarily in how their breathing feels day to day. Because flare-ups come and go, judging whether it is working takes months of tracking attacks and steroid courses. The twice-yearly schedule means fewer appointments than monthly biologics, but missing a visit leaves a long gap. If asthma stays uncontrolled or gets worse after starting, it is worth raising with the care team, since another treatment may suit better.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Exdensur (Depemokimab), what you've noticed, or ask the community a question.